EUVIMEDEUVIMED entdecken
Crossref

Acrodermatitis continua of Hallopeau with insufficient response to ixekizumab and infliximab, successfully treated with a combination of ustekinumab and tofacitinib

Xiaohong Chen, Xiaoyan Huang, Li Ma, Bin Wang, Jiabin Tian, Xiaoming Liu

European Journal of Dermatology · 2023

DOI: 10.1684/ejd.2023.4461 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Dermatology, 2023. Verfasst von Xiaohong Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The University of Hong Kong Shenz hen Hospital, Shenzhen, China 518053. Hauptthemen laut MEDLINE: Acrodermatitis, Exanthema. Die Arbeit wurde bisher 7-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acrodermatitis continua of Hallopeau with insufficient response to ixekizumab and infliximab, successfully treated with a combination of ustekinumab and tofacitinib Acrodermatitis continua of Hallopeau (ACH) is a rare subtype of pustular psoriasis that presents as a sterile,

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrodermatitisExanthemaHumansUstekinumabInfliximabAntibodies, Monoclonal, HumanizedPiperidinesPyrimidines

Substanzen

UstekinumabInfliximabixekizumabAntibodies, Monoclonal, HumanizedtofacitinibPiperidinesPyrimidines

Autor:innen und Institutionen

  • Department of Dermatology, The University of Hong Kong Shenz hen Hospital, Shenzhen, China 518053.
  • Department of Rheumatology, The University of Hong Kong Shenzhen Hospital, Shenzhen, China 518053.

Zitieren

APA

Chen, X., Huang, X., Ma, L., Wang, B., Tian, J., & Liu, X. (2023). Acrodermatitis continua of Hallopeau with insufficient response to ixekizumab and infliximab, successfully treated with a combination of ustekinumab and tofacitinib. European Journal of Dermatology. https://doi.org/10.1684/ejd.2023.4461

Vancouver

Chen X, Huang X, Ma L, Wang B, Tian J, Liu X. Acrodermatitis continua of Hallopeau with insufficient response to ixekizumab and infliximab, successfully treated with a combination of ustekinumab and tofacitinib. European Journal of Dermatology. 2023. doi:10.1684/ejd.2023.4461

BibTeX
@article{Chen2023,
  author = {Chen, Xiaohong and Huang, Xiaoyan and Ma, Li and Wang, Bin and Tian, Jiabin and Liu, Xiaoming},
  title = {Acrodermatitis continua of Hallopeau with insufficient response to ixekizumab and infliximab, successfully treated with a combination of ustekinumab and tofacitinib},
  journal = {European Journal of Dermatology},
  year = {2023},
  doi = {10.1684/ejd.2023.4461}
}
Kostenlos starten →